Member Info for B2HS2L

update:

"Having looked at many accreditations, so far the only ticket that shows use of Primerdesign or Genesig instruments for PCR testing is the Cambridge Clinical Laboratories."

Should state

Having looked at many accreditations, so far the only ticket that shows use of Primerdesign or Genesig assays for PCR testing is the Cambridge Clinical Laboratories.

Apologies if this type of search has been discussed before.

Here is the Schedule of Accreditation for Cambridge Clinical Laboratories Ltd:

https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/9325-Medical-Single.pdf

THE ACCREDITATION IS DATED 26 April 2021.

*When looking at other certificates always check this date first, - some other certificates can be as old as 2018.*

I do not know how often these Accreditations are refreshed, but it might be when a lab stops using one piece of equipment / starts using another.

The schedule of accreditation shows that for materials / products tested by Cambridge Clinical Laboratories:

Oropharyngeal and nasopharyngeal swabs, with Detection of SARS CoV-2 virus RNA (COVID-19) with target gene RdRp,
they use the following equipment:

RNA Extraction using Zymo Quick RNA Viral Kit CLP-195
PCR by Primerdesign COVID-19 qPCR Kit and Myra using the Roche z480 and LC480ii Realtime PCR Platforms

+++

I found this accreditation by using a search of UKAS accredited organisations, browsed by category:
Medical Laboratories / Covid-19 testing.

Here is the link:

https://www.ukas.com/find-an-organisation/browse-by-category/?cat=3733

This list shows Accreditation for many NHS Trusts and other labs.
Having looked at many accreditations, so far the only ticket that shows use of Primerdesign or Genesig instruments for PCR testing is the Cambridge Clinical Laboratories.

I looked (partially) into other categories such as Covid-19 POCT ( https://www.ukas.com/find-an-organisation/browse-by-category/?cat=3750 ),
and Point of care Sampling, (https://www.ukas.com/find-an-organisation/browse-by-category/?cat=3732),
but found no use of genesig or primerdesign instruments, on the Accreditation certificates I viewed.

So I'm wondering where DHSC / NHS are using PROmate or Primerdesign COVID-19 qPCR Kit.

If Poidster is around, can you provide any assistance please.

If your search reveals use of q16 / q32 instruments or Primerdesign / genesig assays, please advise.

"You guys are clearly distressed about this. I am trying to help you as it is causing a huge distraction to the board."

Porky, by continuing to post under both names, you respect nobody here, and the backlash will continue until you STOP.

Just do it.

RBMInvest -
I agree with what you say.
What Porky does not seem to realise is that those reading the sentences constructed by the same person under two handles are insulting to the reader. "Porky is trying to pull the wool over my eyes by trying to make me believe Porky9 and DBR83 are different posters".

Porky, by continuing to post under both names, you respect nobody here, and the backlash will continue until you stop.
You may have fooled LSE, but you are not fooling many other posters here. I advise you to stop right now.

From recent RNS's:

* Expansion underway in US market, with establishment of Novacyt US Inc and appointment of a US General Manager, with up to 10 additional hires expected in H2 2021

* Targeted organic investment has already commenced in the US with the recent appointment of a US General Manager based in California.
Novacyt US Inc, a wholly owned subsidiary of Novacyt S.A., has recently been established and additional investments in new commercial and regulatory hires will occur in H2 2021 to support the new US operations.

So for those computing finger in the air cash piles, - I don't see these costs being discussed.

++++

Is it not evident, that DA, a sales and marketing whizz kid, is going to increase sales and marketing spend in order to introduce fresh initiatives, - else why hire him?

+++++++

FWIW I left a question for the AGM:

If an RNS announced a relationship with ODDO (28th Sep 2020), why are they no longer listed as one of our brokers?

All in good time I think levin -

I can see where you are coming from, but I also see that DA is the guy to make certain calls when appointed.
There ain't no answers before then IMO.

Are you really that short sited TWOSHEDS? - or are you happier day trading?
Sorry your out, - don't do any permanent damage when you start kicking yourself.

_Mr_Big -
I expect Cost of Sales to rise in future, as we can expect DA to throw more cash at sales and marketing when implementing fresh initiatives.

Chief Executive Officers Review:
This is where Novacyt's future lies:

• A leading development capability of in-vitro diagnostics which enables Novacyt to
design, prototype, develop and optimize PCR tests rapidly and deliver best-in-class
clinical performance. Consequently, Novacyt has been at the forefront of a number
of global disease responses, including Zika, Ebola, SARS and now COVID-19
• This includes a proprietary and automated bioinformatics capability which enables
the Company to evaluate over 30,000 full genome sequences daily for the design
of probes and primers to support accelerated product development for first-tomarket PCR assays
• The Company continues to scale this rapid development capability to enable
Novacyt to deliver significant numbers of new PCR tests in the future
• A vertically integrated PCR business which is able to design, develop and
manufacture instruments and reagents in-house to control costs, quality and
performance. The Company can deliver complete PCR work-flow solutions to its
growing customer base
++++

The above and Instrument / Assay sales to private labs.

Someone mention the company being like a cash machine earlier, - I fully agree but with no maximum limit of cash withdrawal!

30,000 full genome sequences daily guarantees that variants cannot make a move without us being aware of future threats.

Equipment you say - you mean instruments not assay?
If you can't provide a link
giz, can you explain what you found?

gizmo -

https://sam.gov/SAM/filedownload?pdfType=1&duns=739777634
we see:

FAR Report. Certification for: PRIMER DESIGN LIMITED ... accordance with FAR 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards."

Lisa Henriet is making an application for PRIMER DESIGN LIMITED to be recognised as a suitable entity to do business with the US Federal Government.

Reading this report, it has the same feeling if you consider
a) Dr Kenny wants to sell, or
b) if she has received an offer she wants to accept

Careful - accessed three pages and have already hit a pay wall.

https://govtribe.com/vendors/primer-design-ltd-u0qd7#related-federal-contract-awards-table

I think this is what you had in mind gizmo, - but cannot see details because of pay wall.

Anybody can provide details of contract award@?

hi gizmo -

I think you meant Primerdesign LIMITED-U0QD7-govtribe - 0 not O?

https://govtribe.com/vendors/primer-design-ltd-u0qd7#related-federal-contract-idvs-table

Can you confirm please?

https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#anchor_1632158924994

"The US government SARS-CoV-2 Interagency Group (SIG) added a new class of SARS-CoV-2 variants designated as Variants Being Monitored (VBM).
This class includes variants with substitutions of concern, including previously designated Variants of Interest (VOIs) or Variants of Concern (VOCs), that are no longer detected or are circulating at very low levels in the United States, and as such, do not pose a significant or imminent risk to public health in the United States."

++++

It is not clear if this new USA classification is to be used outside USA, but the changes SIG group have made are laid out in this document. See the following link for an example of differing virus classification.
Not sure whether WHO recognise the new USA Variants Being Monitored (VBM) class.

++++

https://edition.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-05-11-21/h_fef8fee7189b38a8fdb2aa5b3f01d0bf

May 11, 2021
After WHO reclassifies B.1.617 variant, CDC says it’s still a "variant of interest" in US
From CNN's Jacqueline Howard

Although the World Health Organization now classifies the B.1.617 coronavirus variant first identified in India as a "variant of concern,” it is still classified as a "variant of interest" in the United States.

Classifications of coronavirus variants in the United States may differ from the classifications made by WHO "since the importance of variants may differ by location," the US Centers for Disease Control and Prevention told CNN in an email on Tuesday.

++++

The former link displays which variant is most prevalent in USA.

Jgcw - Do you have this document?
https://novacyt.com/wp-content/uploads/2021/09/NVT-SOC-Rapport-CA-AGM-ENG-.pdf

Airlineboy -
Whatever the reason for your hospital visit, Good Luck to you too, - seems you need it much more than us folk at present.
Sorry to hear your unwell and wishing you a speedy recovery!

Today I followed the instructions posted in the 11:09 post, - I hold shares through HL.
I has no problems, after each of my resolution votes, an on screen message said it had saved my vote.
If I changed my vote, - same thing.
I provided proof of ownership and an e-signature.
I would advise use of said instructions, but it would be easier if you knew how to vote for each of the 26 resolutions first.

source: https://www.glasslewis.com/wp-content/uploads/2017/01/Guidelines_France.pdf

Relevant for those voting to Abstain a resolution.

"These guidelines are intended to supplement Glass Lewis’ Continental Europe Policy Guidelines by highlighting the key policies that we apply specifically to companies listed in France and the relevant regulatory background to which French companies are subject, where they differ from Europe as a whole.
The Continental Europe Policy Guidelines describe the underlying principles, definitions and global policies that Glass Lewis uses when analysing French companies in accordance with best practice standards for France."

Page 2:
VOTING OPTIONS IN FRANCE
We have updated these guidelines to reflect changes to shareholder voting options in line with Law n° 2019-
744 of July 19, 2019 on the simplification, clarification and updating of company law. In particular, "abstain" is
now a separate valid voting option - in addition to current options of “for” and “against”. However, abstentions
will not be counted for the purpose of approving a resolution.

From 13.09.2021 RNS:
"Shareholders can register for the AGM and access to the online meeting by visiting https://novacytagm.eventitdept.com. Shareholders can vote online until midnight on Saturday, 25 September 2021 using the same link. Submissions must include an electronic signature and be accompanied by evidence of shareholding, for example a share certificate or statement of holding."